Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

The remarkable change to the guideline over the last several years, according to Jones, is the adoption of small-molecule inhibitors of B-cell receptor signaling. These include ibrutinib (Imbruvica) and idelalsib (Zydelig). Both agents are accepted as the first best alternative choice for treating relapsed disease, regardless of age, comorbidities, and other factors.

These agents appear to be safe and well-tolerated, and provide a better treatment choice in the relapsed setting compared with chemotherapy, Jones adds.

<<<

View more from the 2016 NCCN Annual Conference

Related Videos
View All
Related Content